Abstract: Method for treating a disease, condition, or syndrome in a subject comprising administering, to a subject in need thereof, a solid or liquid pharmaceutical composition comprising: (a) a high purity botulinum neurotoxin or a complex comprising botulinum neurotoxin, wherein the botulinum neurotoxin is of type A, B, C, D, E, F or G; and (b) a surfactant; wherein the composition does not comprise albumin or a polysaccharide.

Abstract: A method for enhancing an expression of insulin like growth factor 1 receptor in a mesenchymal stem cell is provided. The method includes culturing the mesenchymal stem cell expressing insulin-like growth factor 1 receptor in a medium containing platelet-derived growth factor BB (PDGF-BB) to enhance the expression of insulin like growth factor 1 receptor in the mesenchymal stem cell.

Abstract: An object of the present invention is to provide a cell population comprising adherent cells having low differentiation capacity derived from a fetal appendage, methods for producing or using the same, and a pharmaceutical composition comprising the cell population, in particular wherein the proportion of CD73- and CD90-positive adherent cells derived from a fetal appendage is 90% or more; and the cell population satisfies a relative expression level of LFA-3 gene to the expression level of SDHA gene of 1.0 or more, in particular wherein the relative expression level of HAPLN1 gene to the expression level of SDHA gene is 4.0 or more and/or the relative expression level of CCND2 gene to the expression level of SDHA gene is 1.5 or less, in particular wherein the proportion of the STRO-1-negative adherent cells derived from a fetal appendage is 95% or more.

Abstract: The present invention relates to methods for generating Induced Pluripotent Stem Cells from fibroblast cells. The invention also relates to appropriate culture media used by the method disclosed; pluripotent stem cells, cultures of the pluripotent stem cells, differentiated cells derived from the culture pluripotent stem cells isolated by the methods disclosed and uses for those cells, e.g. therapeutic uses, such as autologous cell therapy procedures.

Abstract: The present disclosure provides for a cell stabilizing medium which comprises gelatin. The cell stabilizing medium help maintain cell viability, e.g., after thawing of a biological material post-cryopreservation.

Abstract: A cellular support system comprises a three-dimensional scaffold structure comprising at least one void. At least one suspended protein bridge spans across the at least one void in the three-dimensional scaffold structure. The suspended protein bridge is capable of supporting cells and promotes three-dimensional cellular growth. In certain aspects, the protein in the suspended protein bridge is an extracellular matrix protein, such as collagens, laminins, fibronectins, and combinations thereof. Such a cellular support system supports thriving cell cultures in three-dimensions emulating cell growth in vivo in an extracellular matrix, including promoting cell remodeling. Methods for making such cellular support systems are also provided.

Abstract: ILC2 cells play a role in the pathogenesis of graft versus host disease (GvHD) and idiopathic pneumonia syndrome (IPS), both conditions associated with allogeneic stem cell transplantation. Infusion of IL-33 activated ILC2 cells into patients with ongoing GvHD or IPS, or prior to onset of GvHD or IPS in susceptible patients, substantially ameliorates the disease and improves survival.

Abstract: Provided herein are methods that relate, in some aspects, to the incubation or culturing, such as to induce stimulation of expansion (proliferation), activation, costimulation and/or survival, of a composition of cells, such as a population of lymphocytes. In some aspects, provided are methods and reagents for the stimulation, e.g., of expansion (proliferation), survival or persistence, activation, costimulation, or other effect, of cell populations that involve binding of agents to a molecule on the surface of the cells, thereby providing one or more signals to the cells. In some cases, the reagents are reagents containing a plurality of binding sites for agents, such as multimerization reagents, and thus the one or more agents are multimerized by reversibly binding to the reagent, e.g., thereby creating a stimulatory reagent (multimerized agent), having stimulatory agents multimerized thereon.

Abstract: The application discloses a method for obtaining MSC-derived cells with improved transplantation properties from MSC, the method comprising a cell size reduction step, wherein said cell size reduction step is characterized by contacting MSC or MSC-derived cells in vitro or ex vivo with heparin or a derivative or analogue thereof at a concentration of at least 0.01 IU/ml. The application further provides a method for obtaining mesenchymal stem cell-derived cells from mesenchymal stem cells (MSC) comprising contacting MSC in vitro or ex vivo with FGF-2, TGF? and at least 0.01 IU/ml heparin or a derivative or analogue thereof. The invention also provides the so-obtained cells and cell populations, as well as further products comprising such and uses thereof.

Abstract: The present disclosure relates to the field of microbial technology, and discloses a composite probiotics and the use thereof. The composite probiotics in the present disclosure is consisted of Bifidobacterium adolescentis CCFM8630, Lactobacillus reuteri CCFM8631, Lactobacillus rhamnosus CCFM1044 and Lactobacillus casei CCFM711, whose effect of alleviating metabolic syndrome is significantly better than that of CCFM8630 or CCFM8631 alone or combination of the two, especially in aspects of lowering contents of serum low density lipoprotein, total cholesterol, and liver triglyceride and contents of serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and IFN-?, and increasing contents of liver glutathione and superoxide dismutase, etc. The extent of decrease or increase is increased by 7.91% to 837.31% compared with the formulations of CCFM8630 or CCFM8631 alone or combination of the two probiotics. The combination of the four probiotics can achieve a significant synergistic effect.

Abstract: The invention relates to the technical filed of tissue engineering and 3D printing, particularly relates to an artificial tissue progenitor and a method for preparing the same.

Abstract: A method of making a spheroid is provided that includes the step of providing a suspension having one or more biologically-relevant materials dispersed within a biocompatible medium. An amount of a hydrophilic material is deposited on a defined area of a super-hydrophobic surface, and a droplet of the suspension is bioprinted onto the hydrophilic material positioned on the super-hydrophobic to thereby create the spheroid.

Abstract: This invention provides methods for diagnosing Alzheimer's disease in a symptomatic human subject, and for determining whether a human subject is predisposed to becoming afflicted with Alzheimer's disease. These methods employ the steps of (a) culturing a subject's lymphocytes with a suitable basement membrane matrix to permit the lymphocytes to aggregate; (b) measuring the resulting lymphocyte aggregation; and (c) based on such measurement, either diagnosing Alzheimer's disease or determining a predisposition to it, as appropriate.

Abstract: Disclosed is a composition for prevention, treatment or ameliorating of atopic dermatitis, the composition containing a monoclonal stem cell obtained via improved subfractionation culturing of a stem cell, a preparation method thereof, and a method for treating atopic dermatitis using the same. According to the improved subfractionation culturing and proliferation method of the stem cell, a desired amount of the monoclonal stem cells may be obtained in a massive manner in a short time via the rapid proliferation of the monoclonal stem cell. The monoclonal mesenchymal stem cell as obtained has an enhanced effect of treatment, prevention or ameliorating of atopic dermatitis, and thus may be usefully used for an atopic dermatitis treatment agent.

Abstract: Methods of treating multiple sclerosis are provided, comprising parenterally administering glatiramer acetate in a sustained-release depot form, and administering adipose-derived stem cells into the central nervous system. According to some aspects the combined treatments provide synergistic effects. In particular the combined therapies offer benefits to progressive forms of multiple sclerosis.

Abstract: Provided herein are methods of making an ECM gel from vascular tissue. Also provided herein are ECM compositions prepared from vascular tissue, and methods of use of those compositions, for example in treatment of aneurysms, and for vascularization or re-vascularization.

Abstract: Described herein is a method of generating in-vitro differentiated airway basal cells and compositions thereof. Also described herein is a method of treating a pulmonary disease comprising administering the in-vitro differentiated airway basal cells and compositions thereof. In another aspect, described herein is a disease model comprising patient-derived or genetically modified in-vitro differentiated airway basal cells and compositions thereof.

Abstract: The present invention provides methods for isolating human cardiac ventricular progenitor cells (HVPs), wherein cultures of day 5-7 cardiac progenitor cells are negatively selected for one or more first markers expressed on human pluripotent stem cells, such as TRA-1-60, to thereby isolate HVPs. The methods can further include positive selection for expression of a second marker selected from the group consisting of JAG1, FZD4, LIFR, FGFR3 and TNFSF9. Large populations, including clonal populations, of isolated HVPs that are first marker negative/second marker positive are also provided. Methods of in vivo use of the HVPs for cardiac repair or to improve cardiac function are also provided. Methods of using the HVPs for cardiac toxicity screening of test compounds are also provided.

Abstract: A method is disclosed for modifying a sheet-shaped cell culture containing at least two types of cells. The method includes soaking the sheet-shaped cell culture in a low nutrient isotonic solution; and changing a content ratio of the at least two cell types constituting the sheet-shaped cell culture.

Abstract: Provided is an agent having an action on a transcellular ion transporter in the intestinal tract, the agent containing a bacterium of the genus Bifidobacterium or the genus Lactobacillus, or a treated product thereof, with the proviso that the case where the ion transporter is a chloride channel and the action is inhibition; the case where the ion transporter is Na+K+Cl? cotransporter (NKCC1) and the action is inhibition; the case where the bacterium is Bifidobacterium infantis 35624; and the case where the bacterium is Lactobacillus salivarius UCC118 are excluded. The agent of the present invention is useful in activation of chloride channels, prevention or treatment of renal diseases, and/or promotion of defecation, and therefore, usable as a medicament, a supplement, etc.